Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30396039 | 0.86 | HCRTR2 (0.33) | HCRTR2HCRTR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25145643 | 0.86 | HCRTR2 (0.33) | HCRTR2HCRTR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31532572 | 0.80 | SLC6A4 (0.38) | HCRTR2HCRTR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21607008 | 0.78 | HRH1 (0.41) | KCNH2SMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31239665 | 0.77 | HCRTR1 (0.34) | HCRTR2HCRTR1LOXL2KCNH2 | |
| SCHEMBL25936181 | 0.77 | HCRTR1 (0.34) | HCRTR2HCRTR1LOXL2KCNH2 | |
| SCHEMBL25252074 | 0.77 | LOXL2 (0.43) | HCRTR2HCRTR1LOXL2 | |
| SCHEMBL25326413 | 0.76 | CHRNB2 (0.41) | — | |
| SCHEMBL25301249 | 0.76 | LOXL2 (0.35) | LOXL2 | |
| SCHEMBL30775929 | 0.76 | LCAT (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | HCRTR2 867/4885HCRTR1 358/4885LOXL2 232/4885 |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | HCRTR2 3019/4885HCRTR1 2560/4885LOXL2 396/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | HCRTR2 867/4885HCRTR1 358/4885LOXL2 232/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | HCRTR2 87/4885HCRTR1 41/4885LOXL2 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.